Clinical Trial Update: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) [Phase 1]

View source ↗

Summary

This Phase 1 trial investigating a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy for systemic lupus erythematosus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy (anti-CD19 CAR-T cell therapy (allogeneic, CRISPR-edited))

Snippet

Sponsor: Caribou Biosciences, Inc. | Conditions: Systemic Lupus Erythematosus, Lupus | Phase 1 | Status: WITHDRAWN